Showing results (1-10 of 186) with videos related to
Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|May 13, 2011
Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodologyJennifer G Gaultney, W K Redekop, Pieter Sonneveld, et al.Expert Review of Anticancer Therapy|June 22, 2012
Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic valueJennifer G Gaultney, William K Redekop, Pieter Sonneveld, et al.Pharmacogenomics|April 1, 2011
Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemiaJennifer G Gaultney, Enrique Sanhueza, Jeroen J Janssen, et al.European Journal of Cancer (Oxford, England : 1990)|September 30, 2006
Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer careCarin A Uyl-de GrootCurrent Opinion in Oncology|June 4, 2005
Health economics: can we afford an unrestricted use of new biological agents in gastrointestinal oncology?Carin A Uyl-de Groot, Giuseppe GiacconePharmacogenomics|January 16, 2018
Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in EuropeJennifer G Gaultney, Therese W Ng, Carin A Uyl-de Groot, et al.Journal of Cancer Policy|July 2, 2022
Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United StatesRemziye Zaim, Ken Redekop, Carin A Uyl-de GrootTranslational Oncology|April 16, 2022
Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancerRemziye Zaim, Ken Redekop, Carin A Uyl-de GrootJournal of Cancer Policy|January 2, 2023
Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancerRemziye Zaim, Ken Redekop, Carin A Uyl-de GrootExpert Review of Pharmacoeconomics & Outcomes Research|June 16, 2010
The economics of improved cancer survival rates: better outcomes, higher costsCarin A Uyl-de Groot, Saskia de Groot, Adri SteenhoekPageof 19